Paris, France

Jean-Christophe Bories


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Immunotherapy: The Contributions of Jean-Christophe Bories

Introduction

Jean-Christophe Bories is a notable inventor based in Paris, France. He has made significant contributions to the field of immunotherapy, particularly in the development of antibodies targeting CD38. His work is particularly relevant in the context of malignant hematological diseases, including multiple myeloma.

Latest Patents

Jean-Christophe Bories holds a patent for "Antibodies having specificity for CD38 and uses thereof." This invention focuses on a new antibody against CD38, which is expressed in various malignant hematological diseases. The patent describes the development of Bi38-3, a bispecific T cell engager that targets CD38 on multiple myeloma cells. Bi38-3 is designed to recruit cytotoxic T cells through the CD3ε, effectively triggering T cell proliferation, cytokine release, and lysis of CD38 positive multiple myeloma cells in vitro. The results indicate that Bi38-3 can eliminate tumor plasma cells isolated from multiple myeloma patients while preserving the integrity of T, B, and NK lymphocytes. Importantly, Bi38-3 has shown efficacy in reducing tumor cells in a xenograft mouse model of human multiple myeloma.

Career Highlights

Throughout his career, Jean-Christophe Bories has worked with esteemed institutions such as Inserm (Institut National de la Santé et de la Recherche Médicale) and Université de Paris. His research has focused on innovative approaches to combat malignant diseases through targeted immunotherapy.

Collaborations

Jean-Christophe has collaborated with notable colleagues, including Armand Bensussan and Maxime Fayon. Their combined expertise has contributed to advancements in the field of immunotherapy.

Conclusion

Jean-Christophe Bories is a pioneering inventor whose work on CD38-targeting antibodies represents a significant advancement in the treatment of multiple myeloma and other hematological malignancies. His contributions to immunotherapy hold promise for improving patient outcomes in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…